IL151499A0 - Human antibodies against eotaxin and their use - Google Patents

Human antibodies against eotaxin and their use

Info

Publication number
IL151499A0
IL151499A0 IL15149901A IL15149901A IL151499A0 IL 151499 A0 IL151499 A0 IL 151499A0 IL 15149901 A IL15149901 A IL 15149901A IL 15149901 A IL15149901 A IL 15149901A IL 151499 A0 IL151499 A0 IL 151499A0
Authority
IL
Israel
Prior art keywords
eotaxin
cat
human antibodies
specific binding
human
Prior art date
Application number
IL15149901A
Other languages
English (en)
Original Assignee
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech
Publication of IL151499A0 publication Critical patent/IL151499A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15149901A 2000-03-03 2001-03-02 Human antibodies against eotaxin and their use IL151499A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18724600P 2000-03-03 2000-03-03
PCT/GB2001/000927 WO2001066754A1 (en) 2000-03-03 2001-03-02 Human antibodies against eotaxin and their use

Publications (1)

Publication Number Publication Date
IL151499A0 true IL151499A0 (en) 2003-04-10

Family

ID=22688187

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15149901A IL151499A0 (en) 2000-03-03 2001-03-02 Human antibodies against eotaxin and their use
IL151499A IL151499A (en) 2000-03-03 2002-08-27 Antibodies of human origin against autotexin and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151499A IL151499A (en) 2000-03-03 2002-08-27 Antibodies of human origin against autotexin and their uses

Country Status (14)

Country Link
US (6) US7323311B2 (ja)
EP (1) EP1259615B1 (ja)
JP (1) JP5198704B2 (ja)
AT (1) ATE414151T1 (ja)
AU (1) AU778392B2 (ja)
BR (1) BRPI0108923B8 (ja)
CA (1) CA2401342C (ja)
DE (1) DE60136527D1 (ja)
GB (1) GB2361704C (ja)
IL (2) IL151499A0 (ja)
MX (1) MXPA02008472A (ja)
NO (1) NO20024179L (ja)
NZ (1) NZ521182A (ja)
WO (1) WO2001066754A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066754A1 (en) 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
EP2383291B1 (en) 2001-08-23 2019-04-17 Rsr Limited Epitope regions of a thyrotropin (TSH) receptor, uses thereof and antibodies thereto
KR20060010730A (ko) * 2003-03-24 2006-02-02 메르시아 파마, 아이엔씨. 염증 상태를 치료하고 예방하기 위한 방법과 조성물
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP1942939B2 (en) 2005-09-30 2021-07-07 Medimmune Limited Interleukin-13 antibody composition
ES2424468T3 (es) 2006-03-27 2013-10-02 Medimmune Limited Miembro de unión para el receptor GM-CSF
CA2939492C (en) 2009-05-13 2019-03-19 Genzyme Corporation Anti-human cd52 immunoglobulins
US8176867B2 (en) 2009-05-28 2012-05-15 Richard J. A. Gayton Watercraft immobilizing system
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
KR101919170B1 (ko) 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
HUE053097T2 (hu) 2015-03-31 2021-06-28 Medimmune Ltd Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
AU2017272804B2 (en) 2016-06-02 2023-11-23 Medimmune Limited Antibodies to alpha-synuclein and uses thereof
WO2017212488A1 (en) * 2016-06-06 2017-12-14 Hadasit Medical Research Service And Development Ltd. Anti-eotaxin for immunoprotection and hepatoprotection
TWI752964B (zh) 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
IE922287A1 (en) 1991-07-15 1993-01-27 Wellcome Found Production of antibodies
IL103758A (en) 1991-12-13 1998-07-15 Akzo Nv Cancer-specific monoclonal antibodies
NZ273052A (en) 1993-09-14 1997-12-19 Imperial College Chemoattractant protein capable of attracting eosinophils and inducing accumulation thereof
US6403782B1 (en) 1995-06-22 2002-06-11 President And Fellows Of Harvard College Nucleic acid encoding eotaxin
US7265201B1 (en) * 1995-06-23 2007-09-04 Millennium Pharmaceuticals, Inc. Human chemotactic cytokine
WO1997012914A1 (en) * 1995-10-05 1997-04-10 Shionogi & Co., Ltd. Novel human cc chemokine
WO1999010534A1 (en) * 1997-08-22 1999-03-04 Center For Blood Research, Inc. Diagnosis and treatment of diseases with eotaxin and antagonists and agonists thereof
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU760854B2 (en) * 1998-06-22 2003-05-22 Immunomedics Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
ES2282133T3 (es) * 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
WO2001066754A1 (en) * 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU778392B2 (en) 2004-12-02
GB0105237D0 (en) 2001-04-18
US20040014132A1 (en) 2004-01-22
JP5198704B2 (ja) 2013-05-15
US7323311B2 (en) 2008-01-29
US20080182319A1 (en) 2008-07-31
JP2003528598A (ja) 2003-09-30
US20140294857A1 (en) 2014-10-02
BRPI0108923B1 (pt) 2018-11-13
US8067564B2 (en) 2011-11-29
DE60136527D1 (de) 2008-12-24
BRPI0108923B8 (pt) 2021-05-25
GB2361704C (en) 2006-08-02
US10577413B2 (en) 2020-03-03
WO2001066754A1 (en) 2001-09-13
US20160257741A1 (en) 2016-09-08
GB2361704A (en) 2001-10-31
MXPA02008472A (es) 2004-03-26
EP1259615A1 (en) 2002-11-27
EP1259615B1 (en) 2008-11-12
GB2361704B (en) 2002-04-10
CA2401342C (en) 2010-08-03
NZ521182A (en) 2004-11-26
US20210277103A1 (en) 2021-09-09
IL151499A (en) 2010-06-30
NO20024179D0 (no) 2002-09-02
US9284589B2 (en) 2016-03-15
ATE414151T1 (de) 2008-11-15
AU3585201A (en) 2001-09-17
US20120270265A1 (en) 2012-10-25
BR0108923A (pt) 2003-04-22
US8715961B2 (en) 2014-05-06
CA2401342A1 (en) 2001-09-13
NO20024179L (no) 2002-11-01

Similar Documents

Publication Publication Date Title
GB2361704B (en) Human antibodies against eotaxin and their use
LU93274I2 (fr) Elotuzumab
LTPA2017043I1 (lt) Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
WO2001078779A3 (en) Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
PL359854A1 (en) Antibodies to human mcp-1
UA92504C2 (en) Anti-myostatin monoclonal antibody
RS20060234A (en) Fully human antibodies against human 4-1bb (cd137)
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
DE60031279D1 (de) Humane monoklonale antikörper gegen prostata spezifisches membranantigen
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
CY1110700T1 (el) Ανασυνδυασμενα αντισωματα αντι-cd30 και χρησεις αυτων
EP1245676A4 (en) HUMANE MONOCLONAL ANTIBODIES AGAINST THE TGF-BETA II RECEPTOR AND THEIR MEDICAL USE
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
TW200517124A (en) Fully human antibodies against human 4-1BB
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2000074729A3 (en) Alpha or beta emitters to fragments in radioimmunotherapy
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ATE372349T1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
WO2005014653A3 (en) Humanized chicken antibodies
TH64455A (th) สารภูมิต้านทาน mcp-1 ในมนุษย์
SI1461360T1 (sl) Konjugati, ki obsegajo protitelo, specifično za domeno ED-B fibronektina, in njihova uporaba za detekcijo in zdravljenje tumorjev